Insider · CIK 0001829899
Janet MJ Hammond
officer
Files at AVIR (Atea Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +58,050 | - | - | 141,801 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | FTax withholding Common Stock | -14,136 | $4.24 | $60k | 127,665 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -46,800 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -11,250 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +177,000 | $0.00 | $0 | 177,000 | Feb 3, 2026 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Common Stock | +46,800 | - | - | 84,272 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Common Stock | +11,250 | - | - | 95,522 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | FTax withholding Common Stock | -14,134 | $3.06 | $43k | 81,388 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -46,800 | $0.00 | $0 | 46,800 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +11,250 | $0.00 | $0 | 11,250 | Feb 4, 2025 |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.